Skip to main content
Premium Trial:

Request an Annual Quote

BioSystem, ProZyme Team on Glycan Sample Prep

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Madison, Wis.-based BioSystem Development and Hayward, Calif.-based ProZyme today announced that they are collaborating on a new sample preparation workflow for glycan sample preparation that combines their respective technologies.

The firm said that the first product will combine ProZyme's enzymatic N-deglycosylation, labeling, and cleanup chemistry with BioSystem Development's AssayMap high-throughput micro-chromatography platform. They added that the resulting platform provides rapid, quantitative N-glycan sample preparation fully enables for any scale of automation.

According to the partners, conventional glycan analysis methods are laborious and expensive and take up to three days or more to perform. They said that their GlykoScreen Rapid Glycosylation Sample Preparation System can process hundreds of samples in three hours or less.

"We believe that the products of this partnership will have a profound impact on advancing the field of glycobiology and look forward to leading this initiative," ProZyme President Jo Wegstein said in a statement.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.